<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: adverse development", fill: "#fbec5d"},
{source: "1: adverse development", target: "1: initial clinical trial", fill: "#fbec5d"},
{source: "1: initial clinical trial", target: "1: technology", fill: "#fbec5d"},
{source: "1: technology", target: "1: prevent us from", fill: "#fbec5d"},
{source: "1: adverse development", target: "3: clinical regulatory", fill: "#fc8eac"},
{source: "3: clinical regulatory", target: "3: delays us from conducting", fill: "#fc8eac"},
{source: "3: delays us from conducting", target: "3: clinical trial", fill: "#fc8eac"},
{source: "3: clinical trial", target: "3: safety issue", fill: "#fc8eac"},
{source: "3: safety issue", target: "3: initial trial", fill: "#fc8eac"},
{source: "3: initial trial", target: "3: enroll patients", fill: "#fc8eac"},
{source: "3: enroll patients", target: "3: completion as", fill: "#fc8eac"},
{source: "3: completion as", target: "3: by investors would likely significantly", fill: "#fc8eac"},
{source: "3: by investors would likely significantly", target: "3: could prevent us from raising", fill: "#fc8eac"},
{source: "3: could prevent us from raising", target: "3: additional", fill: "#fc8eac"},
{source: "3: additional", target: "3: technologies", fill: "#fc8eac"},
{source: "3: clinical regulatory", target: "8: significant additional capital", fill: "#73a9c2"},
{source: "8: significant additional capital", target: "8: product development efforts", fill: "#73a9c2"},
{source: "8: product development efforts", target: "8: acquisition", fill: "#73a9c2"},
{source: "8: acquisition", target: "8: technologies", fill: "#73a9c2"},
{source: "8: technologies", target: "8: intellectual property rights preclinical", fill: "#73a9c2"},
{source: "8: intellectual property rights preclinical", target: "8: clinical testing", fill: "#73a9c2"},
{source: "8: clinical testing", target: "8: products pursuit", fill: "#73a9c2"},
{source: "8: products pursuit", target: "8: regulatory", fill: "#73a9c2"},
{source: "8: regulatory", target: "8: equipment laboratory", fill: "#73a9c2"},
{source: "8: equipment laboratory", target: "8: facilities", fill: "#73a9c2"},
{source: "8: facilities", target: "8: establishment", fill: "#73a9c2"},
{source: "8: establishment", target: "8: production capabilities", fill: "#73a9c2"},
{source: "8: production capabilities", target: "8: intellectual property portfolio general", fill: "#73a9c2"},
{source: "8: intellectual property portfolio general", target: "8: administrative", fill: "#73a9c2"},
{source: "8: administrative", target: "8: capital requirements", fill: "#73a9c2"},
{source: "8: significant additional capital", target: "9: rely on cash reserves", fill: "#339"},
{source: "9: rely on cash reserves", target: "9: proceeds from equity", fill: "#339"},
{source: "9: proceeds from equity", target: "9: debt offerings proceeds from", fill: "#339"},
{source: "9: debt offerings proceeds from", target: "9: intellectual", fill: "#339"},
{source: "9: intellectual", target: "9: property rights equipment facilities", fill: "#339"},
{source: "9: property rights equipment facilities", target: "9: investments", fill: "#339"},
{source: "9: investments", target: "9: government", fill: "#339"},
{source: "9: government", target: "9: arrangements", fill: "#339"},
{source: "9: arrangements", target: "9: operations", fill: "#339"},
{source: "9: rely on cash reserves", target: "15: necessary", fill: "#7fff00"},
{source: "15: necessary", target: "15: development", fill: "#7fff00"},
{source: "15: development", target: "15: expenditures", fill: "#7fff00"},
{source: "15: expenditures", target: "15: potential products", fill: "#7fff00"},
{source: "15: potential products", target: "15: technologies", fill: "#7fff00"},
{source: "15: technologies", target: "15: third parties", fill: "#7fff00"},
{source: "15: necessary", target: "28: regulatory", fill: "#96c"},
{source: "28: regulatory", target: "28: enter clinical trials", fill: "#96c"},
{source: "28: enter clinical trials", target: "28: commercialize", fill: "#96c"},
{source: "28: regulatory", target: "49: manufacturing", fill: "#483c32"},
{source: "49: manufacturing", target: "49: facility", fill: "#483c32"},
{source: "49: facility", target: "49: current sublease agreements", fill: "#483c32"},
{source: "49: manufacturing", target: "START_HERE", fill: "#483c32"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Language_technology">Language technology</a></td>
      <td>Language technology, often called human language technology (HLT), studies methods of how computer programs or electronic devices can analyze, produce, modify or respond to human texts and speech. Working with language technology often requires broad knowledge not only about linguistics but also about computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Information_technology_consulting">Information technology consulting</a></td>
      <td>In management, information technology consulting (also called IT consulting, computer consultancy, business and technology services, computing consultancy, technology consulting, and IT advisory) is a field of activity which focuses on advising organizations on how best to use information technology (IT) in achieving their business objectives.\nOnce a business owner defines the needs to take a business to the next level, a decision maker will define a scope, cost and a time frame of the project.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bachelor_of_Technology">Bachelor of Technology</a></td>
      <td>A Bachelor of Technology (Latin Baccalaureus Technologiae, commonly abbreviated as B.Tech. or BTech; with honours as B.Tech.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_affairs">Regulatory affairs</a></td>
      <td>Regulatory affairs (RA), also called government affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, cosmetics, agrochemicals (plant protection products and fertilizers), energy, banking, telecom etc.  Regulatory affairs also has a very specific meaning within the healthcare industries (pharmaceuticals, medical devices, biologics and functional foods).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Renaissance_Technologies">Renaissance Technologies</a></td>
      <td>Renaissance Technologies LLC, also known as RenTech or RenTec, is an American hedge fund based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analysis. Their signature Medallion fund is famed for the best record in investing history.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_Technologies">United Technologies</a></td>
      <td>United Technologies Corporation (UTC) was an American multinational conglomerate headquartered in Farmington, Connecticut.  It researched, developed, and manufactured products in numerous areas, including aircraft engines, aerospace systems, HVAC, elevators and escalators, fire and security, building automation, and industrial products, among others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Emerging_technologies">Emerging technologies</a></td>
      <td>Emerging technologies are technologies whose development, practical applications, or both are still largely unrealized, such that they are figuratively emerging into prominence from a background of nonexistence or obscurity. These technologies are generally new but also include older technologies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_focus_theory">Regulatory focus theory</a></td>
      <td>Regulatory focus theory (RFT) is a theory of goal pursuit: 444  formulated by Columbia University psychology professor and researcher E. Tory Higgins regarding people's perceptions in the decision making process. RFT examines the relationship between the motivation of a person and the way in which they go about achieving their goal.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_regulatory_network">Gene regulatory network</a></td>
      <td>A gene (or genetic) regulatory network (GRN) is a collection of molecular regulators that interact with each other and with other substances in the cell to govern the gene expression levels of mRNA and proteins which, in turn, determine the function of the cell. GRN also play a central role in morphogenesis, the creation of body structures, which in turn is central to evolutionary developmental biology (evo-devo).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrangement">Arrangement</a></td>
      <td>In music, an arrangement is a musical adaptation of an existing composition. Differences from the original composition may include reharmonization, melodic paraphrasing, orchestration, or formal development.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrangement_of_hyperplanes">Arrangement of hyperplanes</a></td>
      <td>In geometry and combinatorics, an arrangement of hyperplanes is an arrangement of a finite set A of hyperplanes in a linear, affine, or projective space S.  \nQuestions about a hyperplane arrangement A generally concern geometrical, topological, or other properties of the complement, M(A), which is the set that remains when the hyperplanes are removed from the whole space.  One may ask how these properties are related to the arrangement and its intersection semilattice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Floral_design">Floral design</a></td>
      <td>Floral design or flower arrangement is the art of using plant materials and flowers to create an eye-catching and balanced composition or display. Evidence of refined floristry is found as far back as the culture of ancient Egypt.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_use_of_space">Commercial use of space</a></td>
      <td>Commercial use of space is the provision of goods or services of commercial value by using equipment sent into Earth orbit or outer space.  This phenomenon – aka Space Economy (or New Space Economy) – is accelerating cross-sector innovation processes combining the most advanced space and digital technologies to develop a broad portfolio of space-based services.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercial_software">Commercial software</a></td>
      <td>Commercial software, or seldom payware, is a computer software that is produced for sale or that serves commercial purposes. Commercial software can be proprietary software or free and open-source software.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Commercialization_of_love">Commercialization of love</a></td>
      <td>The notion of commercialization of love, that is not to be confused with prostitution (the commercialization of sexual activity), involves the definitions of romantic love and consumerism.\n\n\n== Sociological development ==\nThe commercialization of love is the ongoing process of infiltration of commercial and economical stimuli in the daily life of lovers and the association of monetary and non-monetary symbols and commodities in the love relationships.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Windows_Notepad">Windows Notepad</a></td>
      <td>Windows Notepad is a simple text editor for Windows; it creates and edits plain text documents. First released in 1983 to commercialize the computer mouse in MS-DOS, Notepad has been part of every version of Windows ever since.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_management">Facility management</a></td>
      <td>Facility management, or facilities management, (FM) is a professional management discipline focused on the efficient and effective delivery of logistics and other support services related to real property, it encompasses multiple disciplines to ensure functionality, comfort, safety and efficiency of the built environment by integrating people, place, process and technology, as defined by the International Organization for Standardization (ISO). The profession is certified through Global Facility Management Association (Global FM) member organizations.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Health_facility">Health facility</a></td>
      <td>A health facility is, in general, any location where healthcare is provided. Health facilities range from small clinics and doctor's offices to urgent care centers and large hospitals with elaborate emergency rooms and trauma centers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Facility_location">Facility location</a></td>
      <td>The study of facility location problems (FLP), also known as location analysis, is a branch of operations research and computational geometry concerned with the optimal placement of facilities to minimize transportation costs while considering factors like avoiding placing hazardous materials near housing, and competitors' facilities. The techniques also apply to cluster analysis.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Telecommunications_facility">Telecommunications facility</a></td>
      <td>In telecommunications, a facility is defined by Federal Standard 1037C as:\n\nA fixed, mobile, or transportable structure, including (a) all installed electrical and electronic wiring, cabling, and equipment and (b) all supporting structures, such as utility, ground network, and electrical supporting structures.\nA network-provided service to users or the network operating administration.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hillside_Facility">Hillside Facility</a></td>
      <td>The Hillside Facility, also called the Hillside Support Facility or the Hillside Maintenance Complex, is a maintenance facility of the Long Island Rail Road (LIRR) in Jamaica, Queens, New York City. The Hillside facility was built between 1984 and 1991 on the grounds of a section of Holban Yard, a railroad freight yard.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>STEMCELLS INC      ITEM 1A   RISK FACTORS       Risks Related to our Business       Any <font color="blue">adverse <font color="blue">development</font></font> in the <font color="blue">initial <font color="blue">clinical trial</font></font> for our stem cell     <font color="blue">technology</font> could substantially depress our stock price and <font color="blue">prevent us from</font>     raising  the  capital  we  will  need to further develop our stem cell     <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>To an unusual extent, our ability to progress as a company is <font color="blue"><font color="blue">significant</font>ly</font>     <font color="blue">dependent</font> on a single <font color="blue">early stage</font> <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>Any clinical, <font color="blue">regulatory</font>     or other <font color="blue">development</font> that prevents or <font color="blue">delays us from conducting</font> our initial     <font color="blue">clinical trial</font> for Batten disease, or any <font color="blue">safety issue</font> or adverse side     effect to any patient that occurs during the trial, or the failure of this     <font color="blue">initial trial</font> to <font color="blue">enroll patients</font> and proceed to <font color="blue">completion as</font> anticipated or     to  show the results expected by investors, would likely <font color="blue"><font color="blue">significant</font>ly</font>     depress our stock price and could <font color="blue">prevent us from</font> raising the substantial     <font color="blue">additional</font>  capital  we  will require to further develop our stem cell     <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________    [69]Table of <font color="blue">Contents       </font>Our financial situation is <font color="blue">precarious</font> and, <font color="blue">based on currently</font> estimated     operating expenses, our <font color="blue">existing capital resources may</font> not be sufficient to     fund our <font color="blue"><font color="blue">operations</font> beyond</font> the <font color="blue">next eighteen months</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">incurred <font color="blue">significant</font></font> operating losses and <font color="blue">negative cash flows since</font>     inception</td>
    </tr>
    <tr>
      <td>We have not achieved <font color="blue">profitability</font> and may not be able to realize     <font color="blue">sufficient revenues</font> to achieve or sustain <font color="blue">profitability</font> in the future</td>
    </tr>
    <tr>
      <td>We do     not expect to be profitable in the next <font color="blue">several years</font>, but rather expect to     incur <font color="blue">additional</font> and increasing operating losses</td>
    </tr>
    <tr>
      <td>We have limited liquidity     and  capital  resources and must obtain <font color="blue">significant</font> <font color="blue">additional</font> capital     resources  in order to sustain our <font color="blue">product <font color="blue">development</font> efforts</font> and for     <font color="blue">acquisition</font> of <font color="blue">technologies</font> and <font color="blue">intellectual</font> property rights, preclinical     and <font color="blue">clinical testing</font> of our anticipated products, pursuit of <font color="blue">regulatory</font>     approvals,  <font color="blue">acquisition</font>  of  capital  equipment, laboratory and office     <font color="blue">facilities</font>,  <font color="blue">establishment</font> of <font color="blue">production <font color="blue">capabilities</font></font>, maintaining and     enforcing our <font color="blue">intellectual</font> property portfolio, general and <font color="blue">administrative</font>     expenses and other working <font color="blue">capital requirements</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on cash reserves</font>     and <font color="blue">proceeds from equity</font> and debt offerings, proceeds from the transfer or     sale  of  our  <font color="blue">intellectual</font>  property rights, equipment, <font color="blue">facilities</font> or     <font color="blue">investments</font>,  and  <font color="blue">government</font>  grants  and  funding from collaborative     <font color="blue">arrangements</font>, if obtainable, to fund our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>If we exhaust our cash     reserves and are unable to realize <font color="blue">adequate financing</font>, we may be unable to     meet  operating  <font color="blue"><font color="blue">obligation</font>s</font>  and  be  required to <font color="blue">initiate bankruptcy</font>     <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">existing capital resources may</font> not be sufficient to fund     our  <font color="blue">operations</font>  beyond  the <font color="blue">next eighteen months</font></td>
    </tr>
    <tr>
      <td>We intend to pursue     <font color="blue">opportunities</font> to obtain <font color="blue">additional</font> financing in the <font color="blue">future through equity</font>     and debt <font color="blue">financings</font>, corporate alliances, grants and <font color="blue">collaborative research</font>     <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>The source, timing and <font color="blue">availability</font> of any future financing     will depend principally upon market conditions, interest rates and, more     specifically, on our progress in our exploratory, preclinical and future     <font color="blue">clinical <font color="blue">development</font> programs</font></td>
    </tr>
    <tr>
      <td>Lack of <font color="blue">necessary</font> funds may require us to     delay, scale back or eliminate some or all of our research and product     <font color="blue">development</font> programs and/or our capital <font color="blue">expenditures</font> or to license our     <font color="blue">potential products</font> or <font color="blue">technologies</font> to <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">development</font> programs are based on novel <font color="blue">technologies</font> and are     <font color="blue">inherently risky</font></td>
    </tr>
    <tr>
      <td>We  are subject to the risks of <font color="blue">failure inherent</font> in the <font color="blue">development</font> of     products  based on new <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The novel nature of the therapies     creates  <font color="blue">significant</font>  <font color="blue">challenges</font> in regards to product <font color="blue">development</font> and     <font color="blue">optimization</font>,   <font color="blue">manufacturing</font>,   <font color="blue">government</font>  regulation,  third  party     <font color="blue">reimbursement</font> and <font color="blue">market acceptance</font></td>
    </tr>
    <tr>
      <td>For example, the FDA has <font color="blue">relatively</font>     little experience with stem cell-based therapeutics, and the pathway to     <font color="blue">regulatory</font> approval for our <font color="blue">product <font color="blue">candidates</font> may accordingly</font> be more     complex and <font color="blue">lengthy than</font> the pathway for <font color="blue">new conventional drugs</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">challenges</font> may <font color="blue">prevent us from</font> developing and <font color="blue">commercializing products on</font> a     timely or <font color="blue">profitable basis</font> or at all</td>
    </tr>
    <tr>
      <td>Our <font color="blue">technology</font> is at an <font color="blue">early stage</font> of <font color="blue">discovery</font> and <font color="blue">development</font>, and we may     fail to develop any <font color="blue">commercially</font> acceptable or <font color="blue">profitable products</font></td>
    </tr>
    <tr>
      <td>Before we may market any product, we     must obtain <font color="blue">regulatory</font> approval from the FDA and equivalent foreign agencies     after conducting extensive preclinical studies and <font color="blue">clinical trial</font>s that     <font color="blue">demonstrate</font> that our product <font color="blue">candidates</font> are safe and <font color="blue">effective</font> for each     disease for which we seek approval</td>
    </tr>
    <tr>
      <td>We expect that none of our <font color="blue">cellular therapy product</font>     <font color="blue">candidates</font> will be <font color="blue">commercially</font> available for <font color="blue">several years</font>, if at all</td>
    </tr>
    <tr>
      <td>Our programs are still at the <font color="blue">preclinical phase</font> for our <font color="blue">candidate human</font>     <font color="blue">liver stem cell</font>, and at the <font color="blue">discovery</font> phase for our <font color="blue">candidate human</font> pancreas     stem cell</td>
    </tr>
    <tr>
      <td>While the US Food and Drug Administration (FDA) has permitted     us to <font color="blue">go forward with</font> our proposed Phase I <font color="blue">clinical trial</font> of our <font color="blue">proprietary</font>     <font color="blue">neural stem cell therapy product</font> — HuCNS SC — in Batten disease, and the     Institutional Review Board of the Oregon Health &amp; Science University has     approved  the protocol, that trial has not yet enrolled or treated any     patients and there can be no assurance that the <font color="blue">clinical investigators will</font>     be able to identify suitable <font color="blue">candidates</font> for the trial or of a successful     outcome of the trial if <font color="blue">candidates</font> are enrolled</td>
    </tr>
    <tr>
      <td>We may fail to discover the     stem cells we are seeking, to develop any products, to obtain <font color="blue">regulatory</font>     approvals, to enter <font color="blue">clinical trial</font>s, or to <font color="blue">commercialize</font> any products</td>
    </tr>
    <tr>
      <td>We     may elect to delay or <font color="blue">discontinue preclinical studies</font> or <font color="blue">clinical trial</font>s     <font color="blue">based on unfavorable</font> results</td>
    </tr>
    <tr>
      <td>Any product using stem cell <font color="blue">technology</font> may     fail to:         •  survive and persist in the desired location;         •  provide the <font color="blue">intended <font color="blue">therapeutic benefits</font></font>;                                         21       _________________________________________________________________    [70]Table of <font color="blue">Contents       </font>    •  <font color="blue">properly integrate into existing tissue</font> in the desired manner; or         •  achieve <font color="blue">therapeutic benefits</font> equal to or <font color="blue">better than</font> the standard of     <font color="blue">treatment at</font> the time of testing</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">products may</font> cause undesirable side effects</td>
    </tr>
    <tr>
      <td>Results of     pre<font color="blue">clinical research</font> may not be <font color="blue">indicative</font> of the results that will be     obtained in <font color="blue">later stages</font> of preclinical or <font color="blue">clinical research</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">regulatory</font>     <font color="blue">authorities</font> do not approve our products or if we fail to maintain <font color="blue">regulatory</font>     compliance,  we would be unable to <font color="blue">commercialize</font> our products, and our     business and results of <font color="blue">operations</font> would be harmed</td>
    </tr>
    <tr>
      <td>Furthermore, because     stem cells are a new form of therapy, the <font color="blue">marketplace may</font> not accept any     products we may develop</td>
    </tr>
    <tr>
      <td>If we do succeed in developing products, we will     face  many  potential  <font color="blue">obstacles such as</font> the need to obtain <font color="blue">regulatory</font>     approvals and to develop or obtain <font color="blue">manufacturing</font>, marketing and <font color="blue">distribution</font>     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>In addition, we will face substantial <font color="blue">additional</font> risks such as     <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>Moreover, because our <font color="blue">cell therapy treatments will</font> be <font color="blue">derived from tissue</font> of     <font color="blue">individuals</font> other than the patient (that is, they will be “non-self” or     “allogeneic”  transplant  products),  <font color="blue">patients will</font> require the use of     <font color="blue">immunosuppressive drugs such as cyclosporine</font>, FK506, or others to prevent     rejection  of  the  cells</td>
    </tr>
    <tr>
      <td>While <font color="blue">immunosuppression</font> is now standard in     <font color="blue">connection</font>  with  allogeneic  <font color="blue">transplants</font>  of various kinds, long-term     maintenance  <font color="blue">on immunosuppressive drugs</font> can produce <font color="blue">complications</font> that     include infection, cancer, cardiovascular disease, renal dysfunction and     other  side  <font color="blue">effects depending upon which immunosuppressive regimen</font> is     employed</td>
    </tr>
    <tr>
      <td><font color="blue">Immunosuppression </font>has not <font color="blue">been tested with</font> our <font color="blue">therapies since</font> we     have not yet conducted any <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>Our  success  will  depend in large part on our ability to develop and     <font color="blue">commercialize</font> products that <font color="blue">treat diseases</font> other than Batten disease</td>
    </tr>
    <tr>
      <td>Although we have <font color="blue">initially focused on evaluating</font> our <font color="blue">neural cell therapy</font>     product for the treatment of infantile and <font color="blue">late infantile forms</font> of NCL     (Batten disease), this disease is rare, and the market for treating this     disease is small</td>
    </tr>
    <tr>
      <td>Accordingly, even if we obtain marketing approval for     HuCNS-SC for Batten disease, in order to achieve <font color="blue">profitability</font>, if at all,     we will need to obtain approval for HuCNS-SC and other <font color="blue">potential products</font> to     treat   <font color="blue">additional</font>  diseases  that  present  more  <font color="blue">significant</font>  market     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>We have payment <font color="blue"><font color="blue">obligation</font>s</font> resulting <font color="blue">from real property</font> owned or <font color="blue">leased by</font>     us in Rhode Island, <font color="blue">which diverts funding from</font> our <font color="blue">stem cell research</font> and     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Prior to our <font color="blue">reorganization</font> in 1999 and the <font color="blue">consolidation</font> of our business in     California, we carried out our <font color="blue">former <font color="blue">encapsulated</font> cell therapy programs</font> in     Lincoln,  Rhode  Island, where we also had our <font color="blue">administrative</font> offices</td>
    </tr>
    <tr>
      <td>Although we have vacated the <font color="blue">Rhode Island </font><font color="blue">facilities</font>, we <font color="blue">remain obligated</font> to     make <font color="blue">lease payments</font> and payments for operating costs for our <font color="blue">former science</font>     and <font color="blue">administrative</font> <font color="blue">facility</font>, which we have <font color="blue">leased through</font> June 30, 2013</td>
    </tr>
    <tr>
      <td>These costs, before sub-tenant rental income, amounted to <font color="blue">approximately</font>     dlra1cmam450cmam000 in 2005; our <font color="blue">rent payments will increase over</font> the term of the     lease, and our operating <font color="blue">costs may increase as well</font></td>
    </tr>
    <tr>
      <td>In addition to these     costs of our <font color="blue">former science</font> and <font color="blue">administrative</font> <font color="blue">facility</font>, we are obligated to     make <font color="blue">debt service payments</font> and payments for operating costs of <font color="blue">approximately</font>     dlra450cmam000 per  year  for  our  former  <font color="blue">encapsulated</font>  <font color="blue">cell therapy pilot</font>     <font color="blue">manufacturing</font> <font color="blue">facility</font>, which we own</td>
    </tr>
    <tr>
      <td>We have <font color="blue">currently subleased</font> a portion     of the science and <font color="blue">administrative</font> <font color="blue">facility</font>, and are seeking to sublease the     remaining portion, but we cannot be sure that we will be able to keep any     part of the <font color="blue"><font color="blue">facility</font> subleased</font> for the duration of our <font color="blue">obligation</font></td>
    </tr>
    <tr>
      <td>We have     currently  subleased  the  entire  pilot  <font color="blue">manufacturing</font>  <font color="blue">facility</font> to a     privately-held bio<font color="blue">technology</font> company, but may not be able to sublease or     sell the <font color="blue">facility</font> in the future once the <font color="blue">current sublease <font color="blue">agreement</font>s</font> expire</td>
    </tr>
    <tr>
      <td>These continuing costs <font color="blue"><font color="blue">significant</font>ly</font> reduce our <font color="blue">cash resources</font> and <font color="blue">adversely</font>     affect our ability to fund further <font color="blue">development</font> of our stem cell <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In  addition, changes in <font color="blue">real estate market conditions</font> and <font color="blue">assumptions</font>     regarding the length of time it may take us to either fully sublease, assign     or sell our <font color="blue">remaining interest</font> in the our former research <font color="blue">facility</font> in Rhode     Island may have a <font color="blue">significant</font> impact on and cause large <font color="blue">variations</font> in our     quarter  to quarter results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In 1999, in <font color="blue">connection</font> with     exiting our former research <font color="blue">facility</font> in Rhode Island, we created a reserve     for the estimated <font color="blue">lease payments</font> and operating expenses related to it</td>
    </tr>
    <tr>
      <td>The     reserve is periodically re-evaluated and adjusted based on <font color="blue">assumptions</font>     relevant to <font color="blue">real estate market conditions</font> and the estimated time until we     can either fully sublease, assign or sell our <font color="blue">remaining interest</font>s in the     property</td>
    </tr>
    <tr>
      <td><font color="blue">At December </font>31, 2005, the reserve was dlra7cmam306cmam000</td>
    </tr>
    <tr>
      <td>In 2005 and     2004, we incurred dlra1cmam079cmam000 and dlra1cmam152cmam000 in operating <font color="blue">expenses net</font> of     sub-tenant  income  for this <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>Expenses for this <font color="blue">facility</font> will     fluctuate based on changes in tenant occupancy rates and other operating     expenses related to the lease</td>
    </tr>
    <tr>
      <td>Even though it is our intent to sublease,     assign, sell or <font color="blue">otherwise divest ourselves</font> of our interests in the <font color="blue">facility</font>     at the <font color="blue">earliest possible</font> time, we cannot determine                                         22       _________________________________________________________________    [71]Table of <font color="blue">Contents       </font><font color="blue">with certainty</font> a fixed <font color="blue">date by which such events will</font> occur</td>
    </tr>
    <tr>
      <td>In light of     this uncertainty, based on estimates, we will periodically re-evaluate and     adjust  the reserve, as <font color="blue">necessary</font>, and we may make <font color="blue">significant</font> adverse     <font color="blue">adjustments</font> to the reserve in the future</td>
    </tr>
    <tr>
      <td>We may need but fail to obtain partners to support our stem cell <font color="blue">development</font>     efforts and to <font color="blue">commercialize</font> our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Equity and debt <font color="blue">financings</font> alone may not be sufficient to fund the cost of     developing  our stem cell <font color="blue">technologies</font>, and we may need to rely on our     ability to reach partnering <font color="blue">arrangements</font> to provide financial support for     our stem cell <font color="blue">discovery</font> and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>In addition, in order to     <font color="blue">successfully</font> develop and <font color="blue">commercialize</font> our <font color="blue">technology</font>, we may need to enter     into a wide variety of <font color="blue">arrangements</font> with corporate sponsors, pharmaceutical     companies, universities, research groups and others</td>
    </tr>
    <tr>
      <td>While we have engaged,     and  expect  to  continue  to  engage,  in  <font color="blue">discussions</font> regarding such     <font color="blue">arrangements</font>, we have not reached any <font color="blue">agreement</font>, and we may fail to obtain     any such <font color="blue">agreement</font> on terms acceptable to us</td>
    </tr>
    <tr>
      <td>Even if we <font color="blue">enter into</font> these     <font color="blue">arrangements</font>, we may not be able to satisfy our <font color="blue"><font color="blue">obligation</font>s</font> under them or     renew or <font color="blue">replace them</font> after their <font color="blue">original terms</font> expire</td>
    </tr>
    <tr>
      <td>Furthermore, these     <font color="blue">arrangements</font>  may require us to <font color="blue">grant certain rights</font> to <font color="blue">third parties</font>,     including <font color="blue">exclusive marketing rights</font> to one or more products, may require us     to <font color="blue">issue securities</font> to our <font color="blue">collaborators</font> or may contain other terms that are     burdensome to us</td>
    </tr>
    <tr>
      <td>If any of our <font color="blue">collaborators</font> terminates its <font color="blue">relationship</font>     with  us  or  fails to perform its <font color="blue"><font color="blue">obligation</font>s</font> in a <font color="blue">timely manner</font>, the     <font color="blue">development</font> or <font color="blue">commercialization</font> of our <font color="blue">technology</font> and <font color="blue">potential products</font>     may be <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td>Because the <font color="blue">patient population</font> for NCL, or Batten disease, is very small, we     may  <font color="blue">encounter difficulties</font> in <font color="blue">enrolling subjects</font> in our first planned     <font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">first clinical <font color="blue">application</font></font> we are pursuing — NCL (<font color="blue">also known as</font> <font color="blue">Batten     </font>disease) — has a very small <font color="blue">patient population</font></td>
    </tr>
    <tr>
      <td>From this small population,     we must locate and <font color="blue">enroll patients</font> that satisfy the <font color="blue">specific enrollment</font>     criteria for our planned <font color="blue">clinical trial</font> for this <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>This clinical     trial may be delayed <font color="blue"><font color="blue">significant</font>ly</font> or terminated if we are unable to enroll     a sufficient number of <font color="blue">qualified patients</font></td>
    </tr>
    <tr>
      <td>We have a history of operating losses, and we may fail to obtain revenues or     <font color="blue">become profitable</font></td>
    </tr>
    <tr>
      <td>We expect to continue to incur substantial operating losses in the future in     order to conduct our research and <font color="blue">development</font> <font color="blue">activities</font>, and, if those     <font color="blue">activities</font> are successful, to fund <font color="blue">clinical trial</font>s and other expenses</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font>expenses  include  the  cost of acquiring <font color="blue">technology</font>, product testing,     acquiring <font color="blue">regulatory</font> approvals, establishing production, marketing, sales     and <font color="blue">distribution</font> programs and <font color="blue">administrative</font> expenses</td>
    </tr>
    <tr>
      <td>We have not earned     any <font color="blue">revenues from sales</font> of any product</td>
    </tr>
    <tr>
      <td>All of our past revenues have been     derived from, and any revenues we may obtain for the <font color="blue">foreseeable future</font> are     expected  to be derived from, cooperative <font color="blue">agreement</font>s, research grants,     <font color="blue">investments</font>  and  interest  on  <font color="blue">invested capital</font></td>
    </tr>
    <tr>
      <td>We currently have no     cooperative <font color="blue">agreement</font>s, we have <font color="blue">only one current research grant</font> for our stem     cell <font color="blue">technology</font>, and we may not obtain any such <font color="blue">agreement</font>s or <font color="blue">additional</font>     grants in the future or receive any <font color="blue">revenues from them</font></td>
    </tr>
    <tr>
      <td>If  we  are  unable to protect our patents and <font color="blue">proprietary</font> rights, our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font> will be harmed</td>
    </tr>
    <tr>
      <td>We  own or license a number of patents and <font color="blue">pending patent <font color="blue">application</font>s</font>     related to <font color="blue">various stem</font> and <font color="blue">progenitor cells</font> and methods of deriving and     using them, including <font color="blue">human neural stem cell cultures</font></td>
    </tr>
    <tr>
      <td>Patent protection for     products  such  as those we propose to develop is <font color="blue">highly uncertain</font> and     <font color="blue">involves complex</font> and <font color="blue">continually evolving</font> factual and <font color="blue">legal questions</font></td>
    </tr>
    <tr>
      <td>The     <font color="blue">government</font>al <font color="blue">authorities</font> that consider patent <font color="blue">application</font>s can deny or     <font color="blue"><font color="blue">significant</font>ly</font> reduce the <font color="blue">patent coverage requested</font> in an <font color="blue">application</font> before     or after issuing the patent</td>
    </tr>
    <tr>
      <td>Consequently, we do not know whether any of our     pending <font color="blue">application</font>s will result in the issuance of patents, if any existing     or  future  patents  <font color="blue">will provide sufficient protection</font> or <font color="blue">significant</font>     <font color="blue">commercial advantage</font> or if <font color="blue">others will circumvent</font> these patents</td>
    </tr>
    <tr>
      <td>We cannot     be certain that we were the first to discover the <font color="blue">inventions covered by each</font>     of our <font color="blue">pending patent <font color="blue">application</font>s</font> or that we were the first to <font color="blue">file patent</font>     <font color="blue">application</font>s for <font color="blue">such inventions</font> because patent <font color="blue">application</font>s are secret     until they are published, and because <font color="blue">publication</font> of <font color="blue">discoveries</font> in the     scientific  or patent literature often lags behind actual <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>Patents may not issue from our pending or future patent <font color="blue">application</font>s or, if     issued, may not be of                                         23       _________________________________________________________________    [72]Table of <font color="blue">Contents       </font>commercial  benefit  to us</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">patents may</font> not <font color="blue">afford us</font>     <font color="blue">adequate protection from competing products</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may challenge</font> our     patents or <font color="blue">government</font>al <font color="blue">authorities</font> may declare <font color="blue">them invalid</font> or reduce their     scope</td>
    </tr>
    <tr>
      <td>In the event that a third party has also filed a patent <font color="blue">application</font>     relating to inventions claimed in our patent <font color="blue">application</font>s, we may have to     <font color="blue">participate</font> in <font color="blue">proceedings</font> to determine priority of invention</td>
    </tr>
    <tr>
      <td>Even if a     patent issues, a <font color="blue">court could decide</font> that the patent was <font color="blue">issued invalidly</font></td>
    </tr>
    <tr>
      <td>Because <font color="blue">patents issue</font> for a limited term, our <font color="blue">patents may</font> expire before we     <font color="blue">utilize them profitably</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">most important patents begin</font> to expire in 2015</td>
    </tr>
    <tr>
      <td>Under the procedures of the European Patent Office, <font color="blue">third parties</font> may oppose     our issued European <font color="blue">patents during</font> the <font color="blue">relevant opposition period</font></td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">proceedings</font> and <font color="blue"><font color="blue">oppositions</font> could</font> result in substantial <font color="blue">uncertainties</font> and     cost  for us, even if the <font color="blue">eventual outcome</font> is favorable to us, and the     <font color="blue">outcome might</font> not be favorable to us</td>
    </tr>
    <tr>
      <td>One party has <font color="blue">opposed two</font> of our     granted European patents</td>
    </tr>
    <tr>
      <td>Both <font color="blue">oppositions</font> were heard in 2005, and the     patents were maintained in <font color="blue">somewhat altered</font> form</td>
    </tr>
    <tr>
      <td>The time for appeal has     not yet run and there can be no assurance that the <font color="blue"><font color="blue">opposing party</font> will</font> not     appeal</td>
    </tr>
    <tr>
      <td>While we are confident that, should the decision be <font color="blue">appealed by</font> the     <font color="blue">opposing party</font>, it will be upheld, there can be no guarantee of this</td>
    </tr>
    <tr>
      <td>If we     are <font color="blue">ultimately unsuccessful</font> in our defense of the opposed patents, all     claimed  rights  in  the  opposed  patents  will  be  lost  in Europe</td>
    </tr>
    <tr>
      <td>US <font color="blue">counterparts</font> to these patents are part of our <font color="blue">issued patent portfolio</font>;     they are not subject to opposition, since that procedure does not exist     under US patent law, but other types of <font color="blue">proceedings</font> may be available to     <font color="blue">third parties</font> to contest our US patents</td>
    </tr>
  </tbody>
</table>